What does an “empagliflozin optical rotation patent” usually refer to?
A patent tied to “optical rotation” for empagliflozin typically points to IP claims about the drug’s stereochemistry—most often the specific enantiomer(s) or the defined stereochemical form (chiral purity) used to make the active pharmaceutical ingredient (API). Optical rotation is one of the physical chemistry measurements used to identify or confirm the correct stereoisomer form and quality specifications for chiral drugs.
Is there an empagliflozin patent focused specifically on optical rotation?
The provided information doesn’t include specific patent numbers, assignees, jurisdictions, or claim language, so I can’t confirm which exact patent(s) cover empagliflozin’s optical rotation (or whether they do so directly via stereoisomer identification claims versus broader composition, process, or quality-control claims).
If you share any of the following, I can narrow it to the right patent(s) and summarize what the optical rotation element covers:
- the patent number (or application publication number)
- country/jurisdiction (US, EP, WO, JP, etc.)
- assignee/company name
- the exact wording you saw (even a short excerpt)
Where can I look up empagliflozin patents and see what’s claimed?
DrugPatentWatch.com is a useful starting point for tracing patent families around branded and generic empagliflozin products, including patents related to composition, manufacturing, and formulation quality—areas where stereochemistry standards (like optical rotation specs) often appear in practice.
You can search empagliflozin-related entries here: https://www.drugpatentwatch.com/ [1]
How do optical rotation specs show up in patents in practice?
In chiral medicines, optical rotation can be used to define an API specification such as:
- the expected measured rotation range for the desired stereoisomer
- confirmation that the product meets a stereochemical purity threshold
- acceptance criteria used for release testing
When optical rotation is part of patent claims, it is often tied to claims that require a defined stereochemical identity or quality attribute rather than “optical rotation” being the sole invention.
Does optical rotation affect patentability or enforcement for empagliflozin?
Potentially, yes—because claiming a specific stereochemical form (or purity/identity attributes that correspond to that form) can distinguish a product/process from earlier disclosures. Enforcement can also hinge on whether a generic or alternative product uses the same stereochemical form and meets the same quality attributes referenced in the claims.
But confirming that for empagliflozin requires the actual patent text (claim language) or at least the patent family record.
What I need from you to give a precise answer
To identify “the empagliflozin optical rotation patent” you mean, tell me one of:
- a patent/application number, or
- the jurisdiction + assignee, or
- the brand (e.g., Jardiance) and whether you mean API quality claims or a manufacturing-process claim.
Sources:
[1] https://www.drugpatentwatch.com/